Abstract
1 The whole blood concentrations of propranolol have been compared, over a 48 h period, in twelve healthy male volunteers dosed with a 160 mg long-acting capsule formulation (LA, United Kingdom patent application No. 23114/77) and three standard tablet regimens; 160 mg once a day (CP160), 80 mg twice a day (CP80) and 40 mg four times a day (CP40).
2 The mean peak blood level for the long-acting formulation was significantly lower than that obtained with the 160 mg standard tablet. However, from 12 h on the mean levels for the long-acting formulation were higher.
3 The mean peak blood level for the long-acting formulation was significantly lower than that obtained with the 80 mg twice a day regimen and this difference was maintained up to 24 h. Thereafter, however, the situation was reversed.
4 The mean blood levels between 12 and 15 h were lower for the long-acting formulation when compared with the 40 mg four times a day regimen. At all other times, however, the observed levels were very similar.
5 The profiles achieved with the long-acting formulation in two separate studies were almost identical over a 48 h period.
6 The percentage reductions in exercise heart rate over the 3-24 h post dosing period were similar for the long-acting formulation and the two standard regimens studied (i.e. CP40 and CP80) when compared with placebo.
7 In the 2 h post dosing period the 80 mg twice a day regimen produced a significant reduction in the post-exercise systolic blood pressure when compared with the long-acting formulation.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Aellig W. H. beta-Adrenoceptor blocking activity and duration of action of pindolol and propranolol in healthy volunteers. Br J Clin Pharmacol. 1976 Apr;3(2):251–257. doi: 10.1111/j.1365-2125.1976.tb00600.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Berglund G., Andersson O., Hansson L., Olander R. Propranolol given twice daily in hypertension. Acta Med Scand. 1973 Dec;194(6):513–515. doi: 10.1111/j.0954-6820.1973.tb19483.x. [DOI] [PubMed] [Google Scholar]
- Chidsey C. A., Morselli P., Bianchetti G., Morganti A., Leonetti G., Zanchetti A. Studies of the absorption and removal of propranolol in hypertensive patients during therapy. Circulation. 1975 Aug;52(2):313–318. doi: 10.1161/01.cir.52.2.313. [DOI] [PubMed] [Google Scholar]
- Evans G. H., Nies A. S., Shand D. G. The disposition of propranolol. 3. Decreased half-life and volume of distribution as a result of plasma binding in man, monkey, dog and rat. J Pharmacol Exp Ther. 1973 Jul;186(1):114–122. [PubMed] [Google Scholar]
- Gatley M. S. To be taken as directed. J R Coll Gen Pract. 1968 Jul;16(1):39–44. [PMC free article] [PubMed] [Google Scholar]
- Shand D. G. Individualization of propranolol therapy. Med Clin North Am. 1974 Sep;58(5):1063–1069. doi: 10.1016/s0025-7125(16)32102-2. [DOI] [PubMed] [Google Scholar]
- Shand D. G., Nuckolls E. M., Oates J. A. Plasma propranolol levels in adults with observations in four children. Clin Pharmacol Ther. 1970 Jan-Feb;11(1):112–120. doi: 10.1002/cpt1970111112. [DOI] [PubMed] [Google Scholar]
- Zacharias F. J., Cowen K. J., Prestt J., Vickers J., Wall B. G. Propranolol in hypertension: a study of long-term therapy, 1964-1970. Am Heart J. 1972 Jun;83(6):755–761. doi: 10.1016/0002-8703(72)90206-2. [DOI] [PubMed] [Google Scholar]